BACKGROUND

A short notice opportunity exists to acquire the IPR of an established biotech company.

BUSINESS OVERVIEW

• The opportunity includes a dual-series chemistry platform, enabling multiple potential development paths and strong positioning in a competitive IP landscape.
• Confidential portfolio of early-stage assets focused on a differentiated approach to modulating coagulation pathways.
• IPR rights to include trademarks, PCT applications, technical details etc.
• Right to pursue future use of the company's name and trading style, intellectual property, website, domain names etc.

The intellectual property is subject to an existing licence with the University of Leeds.  Any transaction will be conditional upon the consent and approval of the University for continued collaboration.

IMPORTANT

This briefing sheet contains information supplied by company personnel. LSH provides no warranties or indemnities in respect of such information. All interested parties must rely on their own investigations when reviewing this opportunity.